Biologics Approval Record Is “Excellent” Under PDUFA, FDA Says
Executive Summary
The Center for Biologics Evaluation & Research's new product review performance has been "excellent" under the user fee program, FDA said
You may also be interested in...
Antisense Reviews Could Move To CBER; FDA Defends Reorganization On Hill
Antisense oligonucleotide products may be transferred from the Center for Drug Evaluation & Research to the Center for Biologics Evaluation & Research under the pending reorganization of review responsibilities
Antisense Reviews Could Move To CBER; FDA Defends Reorganization On Hill
Antisense oligonucleotide products may be transferred from the Center for Drug Evaluation & Research to the Center for Biologics Evaluation & Research under the pending reorganization of review responsibilities
Erbitux Hearing May Feature FDA Reviewer Communication Policies
The House Energy & Commerce Committee's Oct. 10 follow-up hearing on the Erbitux (cetuximab) BLA may serve as a venue to discuss FDA's internal policy on communication between reviewers and sponsors over pending applications